Revolution Medicines received FDA approval for an expanded access program for its pancreatic cancer drug, daraxonrasib, following positive Phase 3 trial results showing significant survival benefits. The drug demonstrated a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy, sparking high patient demand. Hospitals face operational challenges managing individual patient requests and monitoring treatment. The company aims for full FDA approval but has not set a timeline, while its stock has recently declined despite strong year-to-date gains.
Glancy Prongay Wolke & Rotter LLP has started a securities fraud investigation into Alphatec Holdings following the company's Q1 2026 earnings report, which missed revenue estimates and lowered its full-year outlook. Alphatec reported lower deliverie...
SaintQuant has officially launched its AI-driven quantitative crypto trading platform, offering retail investors easy, no-code access to automated trading strategies. This launch coincides with Bitcoin surpassing $82,000 and record institutional infl...
SpaceX is expected to release its IPO prospectus soon, aiming to raise $70-75 billion and seek a valuation around $1.75 trillion, which would make it one of the most valuable public companies globally. The company's revenue is largely driven by Starl...
The global protective films market is projected to grow from $5.81 billion in 2026 to $7.62 billion by 2031, at a CAGR of 5.6%. Growth is fueled by rising demand for surface protection during manufacturing, transportation, and installation, especiall...
IDenta Corp reported its strongest quarter ever in Q1 2026, with revenues rising to $520,983 from $174,799 in Q1 2025. The company saw significant profit improvements, turning a net loss into a net profit of $29,860. Growth was driven by expanding in...
